Company overview
Basic information
Company name
Pharmafina, MB
Company code
306632209
Registered address
Vilnius, Albanų g. 20-2, LT-11332
Registration date
2023-11-22
Company age: 2 y. 11 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Email
Not disclosed
(personal)
Website
None
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Small partnership
NACE activity
Business and other management consultancy activities
Ownership form
Private without foreign capital
MB "Pharmafina"
Company code: 306632209
Address: Vilnius, Albanų g. 20-2, LT-11332
Description
This description was generated by artificial intelligence.
Pharmafina, MB (company code 306632209) is an operational private small partnership registered on 2023-11-22. It is a micro-sized entity with CEO-only governance and belongs to the sector of national private non-financial companies. The company is privately owned, with more than 50% of authorised capital held by Lithuanian natural and legal persons and no foreign investor capital. Its registered activity is N.70.20.00, Business and other management consultancy activities. The company is based in Vilnius, Albanu g. 20-2, in Vilniaus m. municipality, Vilniaus county.
Financially, Pharmafina expanded strongly after its short first period of activity in 2023, when it generated €1.6K in revenue and €1.5K in net profit over 39 days. In 2024, revenue increased to €197.6K and net profit to €144.9K. In 2025, revenue rose further to €292.3K, up 47.9% year on year, while net profit reached €224.3K and the profit margin was 76.7%. At the end of 2025, equity stood at €190.8K, total assets at €204.3K and liabilities at €13.5K.
Financially, Pharmafina expanded strongly after its short first period of activity in 2023, when it generated €1.6K in revenue and €1.5K in net profit over 39 days. In 2024, revenue increased to €197.6K and net profit to €144.9K. In 2025, revenue rose further to €292.3K, up 47.9% year on year, while net profit reached €224.3K and the profit margin was 76.7%. At the end of 2025, equity stood at €190.8K, total assets at €204.3K and liabilities at €13.5K.
Download a detailed company report
Make confident decisions with all the information about Pharmafina, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.